Armie Margaret Lee

|RSS

Armie Margaret Lee is a reporter covering private equity. Previously, she was at InvestmentWires, an online media company that focuses on the mutual fund and 401(k) industries. She has also covered real estate and banking for Miami Today and technology for Manila Times in the Philippines.

By

Armie Margaret Lee

 | Dec 11, 2017 | 9:40 AM EST
Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of...
RMPIA
By

Armie Margaret Lee

 | Dec 8, 2017 | 9:37 AM EST
France-based firm said its Phase 2 study of eryaspase (Graspa) in acute myeloid leukemia did not achieve its primary endpoint of overall survival.
By

Armie Margaret Lee

 | Dec 7, 2017 | 9:26 AM EST
The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major...
By

Armie Margaret Lee

 | Dec 6, 2017 | 9:30 AM EST
The FDA has accepted the Boulder, Colo.-based firm's supplemental New Drug Application for ovarian cancer therapy rucaparib and granted priority...
By

Armie Margaret Lee

 | Dec 5, 2017 | 9:34 AM EST
The Newark, Calif.-based firm unveiled positive top-line results from a pair of studies evaluating RT002 for the treatment of glabellar, or frown,...
By

Armie Margaret Lee

 | Dec 4, 2017 | 9:29 AM EST
The Cambridge, Mass.-based Ironwood unveiled top-line data from a pair of Phase 2a studies evaluating IW-1973 in patients that have type 2 diabetes...
By

Armie Margaret Lee

 | Dec 1, 2017 | 9:35 AM EST
Versartis, Adamas and DBV Technologies were among the biotech movers ahead of the market open on Dec. 1.
By

Armie Margaret Lee

 | Nov 30, 2017 | 9:25 AM EST
The New Haven, Conn.-based firm on Nov. 29 unveiled a deal to acquire The Medicines Co.'s infectious disease unit.
By

Armie Margaret Lee

 | Nov 28, 2017 | 9:32 AM EST
The Fremont, Calif.-based firm and Kyowa Hakko Kirin signed a license pact for Ardelyx's lead investigational product, tenapanor.
RMPIA
By

Armie Margaret Lee

 | Nov 27, 2017 | 9:30 AM EST
Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of...
I missed my own entry on this one....but the setup is starting to play out in ADBE.  ...
Why would anyone look to buy Consolidated Edison (ED) in the face of rising interest rates...
This chart is coming around here, we like the bull flag here, a breakout would be imminent...

BEST IDEAS

News Breaks

Powered by

COLUMNIST TWEETS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.